Safety Evaluation of the Advanced Hybrid Closed Loop (AHCL) System

Completed · Not applicable

Conditions studied: Type 1 Diabetes Mellitus

In brief

This study is a Safety Evaluation of the Advanced Hybrid Closed Loop (AHCL) System in Type 1 Adult and Pediatric Subjects.

Key facts

Study ID

NCT03959423

Run by

Medtronic MiniMed, Inc.

People needed

288

Starts

2019-07-24

Expected to finish

2023-10-27

Last updated by the study team

2025-01-14

Who can join

Age: 7 and older, up to 75. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Subject is age 7-75 years at time of Screening
• Subjects 14-75 years of age: A clinical diagnosis of type 1 diabetes for 2 years or more as determined via medical record or source documentation by an individual qualified to make a medical diagnosis
• Subjects 7-13 years of age: A clinical diagnosis of type 1 diabetes for 1 year or more as determined via medical record or source documentation by an individual qualified to make a medical diagnosis Study-specific inclusion criteria
• Subject is willing to perform ≥ 4 finger stick blood glucose measurements daily
• Subject is willing to perform required sensor calibrations
• Subject is willing to wear the system continuously throughout the study
• Subject must have a minimum daily insulin requirement (Total Daily Dose) of greater than or equal to 8 units
• Subject has a Glycosylated hemoglobin (HbA1c) less than 10% (as processed by Central Lab) at time of Screening visit Note: All HbA1c blood specimens will be sent to and tested by a NGSP certified Central Laboratory. HbA1c testing must follow National Glycohemoglobin Standardization Program (NGSP) standards.
• Subject has TSH in the normal range OR if the TSH is out of normal reference range the Free T3 is below or within the lab's reference range and Free T4 is within the normal reference range.
• Pump therapy for greater than 6 months prior to screening (with or without CGM experience)
• Subject must have a companion or caregiver available at night for the duration of the study period who resides (or will live) in in the same building (or home). A companion or caregiver should also be available during exercise challenges in the same building, home or location (if not at home). This requirement may be verified by subject report at screening visit.
• Subject willing to upload data from the study pump, must have Internet access and a computer system that meets the requirements for uploading the study pump
• If subject has celiac disease, it has been adequately treated as determined by the investigator
• Subject is willing to take one of the following insulins and can financially support the use of either of the 2 insulin preparations throughout the course of the study (i.e. co-payments for insulin with insurance or able to pay full amount)
• Humalog™* (insulin lispro injection)
• NovoLog™* (insulin aspart)
• Subjects with history of cardiovascular event 1 year or more from the time of screening must have an EKG within 6 months prior to screening or during screening. If subject has an abnormal EKG, participation is allowed if there is clearance from a cardiologist
• Subjects with the 3 or more cardiovascular risk factors listed below must have an EKG within 6 months prior to screening or during screening. If subject has an abnormal EKG, participation is allowed if there is clearance from a cardiologist
• a. Cardiovascular risk factors include:
• Age >35 years
• Type 1 diabetes of >15 years' duration
• Presence of any additional risk factor for coronary artery disease
• Presence of microvascular disease (proliferative retinopathy or nephropathy, including microalbuminuria)
• Presence of peripheral vascular disease
• Presence of autonomic neuropathy

You may not qualify if…

• Subject has a history of 1 or more episodes of severe hypoglycemia, which resulted in any the following during the 6 months prior to Screening:
• Medical assistance (i.e. Paramedics, Emergency Room (ER) or Hospitalization)
• Coma
• Seizures
• Subject has been hospitalized or has visited the ER in the 6 months prior to Screening resulting in a primary diagnosis of uncontrolled diabetes
• Subject has had Diabetic Ketoacidosis (DKA) in the 6 months prior to Screening.
• Subject has Hypoglycemia Unawareness, as measured by the Gold questionnaire (Gold, MacLeod et al. 1994) at Screening
• Subject is unable to tolerate tape adhesive in the area of sensor placement
• Subject has any unresolved adverse skin condition in the area of sensor placement (e.g., psoriasis, dermatitis herpetiformis, rash, Staphylococcus infection)
• Women of child-bearing potential who have a positive pregnancy test at Screening or plan to become pregnant during the course of the study
• Females who are sexually active and able to conceive will be excluded if they are not using an effective method of contraception and do not agree to continue using an effective method of contraception for the duration of the study as determined by investigator.
• Subject has had any of the following cardiovascular events within 1 year of screening: myocardial infarction, unstable angina, coronary artery bypass surgery, coronary artery stenting, transient ischemic attack, cerebrovascular accident, angina, congestive heart failure, ventricular rhythm disturbances or thromboembolic disease
• Subject is being treated for hyperthyroidism at time of Screening
• Subject has a diagnosis of adrenal insufficiency
• Subject has taken any oral, injectable, or intravenous (IV) glucocorticoids within 8 weeks from time of Screening, or plans to take any oral, injectable, or IV glucocorticoids during the course of the study
• Subject is actively participating in an investigational study (drug or device) wherein he/she has received treatment from an investigational study drug or investigational study device in the last 2 weeks
• Subject is currently abusing illicit drugs
• Subject is currently abusing marijuana
• Subject is currently abusing prescription drugs
• Subject is currently abusing alcohol
• Subject is using pramlintide (Symlin), DPP-4 inhibitor, liraglutide (Victoza or other GLP-1 agonists), metformin, canagliflozin (Invokana or other SGLT2 inhibitors) at time of Screening
• Subject has a history of visual impairment which would not allow subject to participate in the study and perform all study procedures safely, as determined by the investigator
• Subject has elective surgery planned that requires general anesthesia during the course of the study
• Subject has a sickle cell disease, hemoglobinopathy; or has received red blood cell transfusion or erythropoietin within 3 months prior to time of Screening
• Subject plans to receive red blood cell transfusion or erythropoietin over the course of study participation

Where it is running

• Arkansas Diabetes and Endocrinology Center — Little Rock, Arkansas, United States
• Scripps Whittier Diabetes Institute — La Jolla, California, United States
• SoCal Diabetes — Torrance, California, United States
• Diablo Clinical Research — Walnut Creek, California, United States
• Barbara Davis Center - Adults — Aurora, Colorado, United States
• Barbara Davis Center - Pediatric — Aurora, Colorado, United States
• Yale Diabetes Research Program — New Haven, Connecticut, United States
• University of South Florida — Tampa, Florida, United States
• Atlanta Diabetes Associates — Atlanta, Georgia, United States
• Southeastern Endocrine — Roswell, Georgia, United States
• Rocky Mountain Diabetes Center — Idaho Falls, Idaho, United States
• International Diabetes Center — Minneapolis, Minnesota, United States
• AM Diabetes & Endocrinology Center — Bartlett, Tennessee, United States
• Texas Endocrinology — Austin, Texas, United States
• Diabetes and Glandular Disease Clinic — San Antonio, Texas, United States
• Rainier Clinical Research — Renton, Washington, United States
• Seattle Children's Hospital and Medical Center — Seattle, Washington, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.